Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

01.11.2022 | short review

ASCO 2022 update: (neo-)adjuvant treatment of colorectal cancer

verfasst von: Dr. Gudrun Piringer, MSc

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Summary

In this short review, two late breaking abstracts of neoadjuvant and adjuvant treatment concepts for colorectal cancer presented at ASCO 2022 will be highlighted. Both treatment concepts have the potential to change the standard of care in a subgroup of colorectal cancer patients in the future.
Vorheriger Artikel ASCO update: hepatocellular and cholangiocellular carcinoma
Nächster Artikel Best of ASCO 2022—central nervous system tumors
Literatur
1.
Sauer R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731–40.CrossRef
2.
Bahadoer R, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (Rapido) a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;222:29–42.CrossRef
3.
4.
Cercek A, et al. Mismatch repair-deficient rectal cancer and resistance to neoadjuvant chemotherapy. Clin Cancer Res. 2020;26:3271–9.CrossRef
5.
André T, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383:2207–18.CrossRef
6.
Overmann MJ, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018;36:773–9.CrossRef
7.
Cercek A, et al. PD‑1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Eng J Med. 2022;386:2363–76.CrossRef
8.
Sargent D, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2009;27:872–7.CrossRef
9.
Tie J, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med. 2016;8:346.CrossRef
10.
Tie J, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Eng J Med. 2022;386:2261–72.CrossRef
Metadaten
Titel
ASCO 2022 update: (neo-)adjuvant treatment of colorectal cancer
verfasst von
Dr. Gudrun Piringer, MSc
Publikationsdatum
01.11.2022
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2022
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-022-00841-6

Weitere Artikel der Ausgabe 4/2022

ASCO update—best of the best

  • editorial

Bilateral primary breast lymphoma in a pregnant woman: a case report and literature review

  • case report

Best of ASCO 2022—central nervous system tumors

  • Open Access
  • short review

Neuroendocrine neoplasms revisited—the challenges of reclassifying tumor

  • editorial

Best of ASCO 2022—bladder cancer

  • Open Access
  • short review

Endometrial cancer: news from ASCO

  • Open Access
  • short review